Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite.

@article{Okerholm1987BiotransformationAP,
  title={Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite.},
  author={Richard A Okerholm and Kwong Yin Chan and Jia Lang and Gary A. Thompson and Stephen J. Ruberg},
  journal={The American journal of cardiology},
  year={1987},
  volume={60 5},
  pages={21C-26C}
}
Enoximone possesses both positive inotropic and vasodilatory activities and may be useful in the treatment of patients with congestive heart failure (CHF). In all animal species investigated (rat, dog, monkey and man), the major urinary metabolite is the sulfide oxidation product (sulfoxide); very little unchanged drug appears in urine. Both in vitro and in vivo animal studies indicate reversibility of the sulfoxidation reaction; therefore, it is presumed that sulfoxidation is reversible in man… CONTINUE READING